TLPH

Talphera Inc

Add to Watchlist

Advanced Chart

0.415

-0.03(-6.748%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.444

Open

0.444

VWAP

0.42

Vol

109.53K

Mkt Cap

8.51M

Low

0.415

Amount

46.30K

EV/EBITDA(TTM)

Total Shares

20.50M

3.12M

EV/OCF(TTM)

P/S(TTM)

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q3

0.00

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Talphera, Inc. (TLPH) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -18.88%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-18.88%

In Past 3 Month

1 Analyst Rating

622.89% Upside

Wall Street analysts forecast TLPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLPH is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

622.89% Upside

Current: 0.415

Low

3.00

Averages

3.00

High

3.00

622.89% Upside

Current: 0.415

Low

3.00

Averages

3.00

High

3.00

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

2025-04-01

Reason

HC Wainwright & Co.

Ed Arce

Price Target

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

2025-01-21

Reason

HC Wainwright & Co.

Ed Arce

Price Target

2025-01-21

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

2024-08-16

Reason

HC Wainwright & Co.

Ed Arce

Price Target

2024-08-16

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Talphera Inc (TLPH.O) is -0.87, compared to its 5-year average forward P/E of -2.19. For a more detailed relative valuation and DCF analysis to assess Talphera Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.19

Current PE

-0.87

Overvalued PE

0.49

Undervalued PE

-4.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.71

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.40

Undervalued EV/EBITDA

-4.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.53

Current PS

8.78

Overvalued PS

35.31

Undervalued PS

-6.26